Objective: Recent studies demonstrate that microRNAs show promising potential, including angiogenesis, in therapeutic intervention. ) is reported to regulate angiogenesis by blocking Sprouty-related EVH1 domain-containing protein 1 (SPRED1), an endogenous inhibitor of vascular endothelial cell growth factor. In this study, we investigated the angiogenic effects of the sustained release of miR-126 loaded with poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) in a murine hindlimb ischemia model.
Recently, endogenous small noncoding RNAs, called microRNAs (miRNAs), have been identified as important post-transcriptional inhibitors of gene expression in many biologic processes. [1] [2] [3] Moreover, miRNAs have been shown to play important roles in regulating the pathophysiologic process of various diseases, including vascular diseases. [4] [5] [6] The biologic roles of miRNAs in vascular diseases have led to an increased interest in miRNA regulation as a therapeutic and diagnostic approach. Recent studies demonstrated that miRNAs show promising potential in therapeutic interventions directed toward ischemic diseases. 7, 8 Several specific miRNAs have been identified as angiogenic regulators. Among them, miRNA-126 (miR-126) is reported to regulate angiogenesis by blocking Sproutyrelated EVH1 domain-containing protein 1 (SPRED1), an endogenous inhibitor of vascular endothelial cell growth factor (VEGF) through the intracellular VEGF receptor pathway. [9] [10] [11] [12] Accordingly, deletion of the miR-126 affects vascular integrity and angiogenesis. 9 ,10 miR-126 is known to be located in intron 7 of the egfl7 gene and is highly expressed in endothelial cells. 13, 14 These findings imply that miR-126 could be an attractive target for therapeutic intervention for ischemic diseases.
To maximize the therapeutic effect of miRNA-based therapies, a drug delivery system (DDS) for the target tissue optimized for miRNA delivery is indispensable. Poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs), a family of Food and Drug Administration-approved biodegradable polymers, are reported to have excellent biocompatibility and biodegradability and are popular among the various available biodegradable polymers because of their long clinical experience, favorable degradation characteristics, and possibility of sustained drug delivery. 15, 16 It is also reported that the PLGA NPs are effectively and rapidly incorporated in endothelial cells. 17 Here, we hypothesized that the DDS using PLGA NPs and miR-126 would serve as a novel strategy for the treatment of ischemic diseases, including clinical limb ischemia. In this study, we investigated the angiogenic effects of the local sustained release of miR-126 loaded with PLGA NPs in a murine hindlimb ischemia model.
METHODS
Animals. Male 10-week-old C57BL/6J wild-type mice were purchased from CLEA Japan (Osaka, Japan). All animal experimental protocols were approved by the Animal Experimentation Committee of Kyoto University. All animal experiments were performed according to the Guidelines for Animal Experiments of Kyoto University, which conform to Japanese law and the Guide for the Care and Use of Laboratory Animals.
Preparation of miR-126-loaded PLGA NPs. We prepared cholesterol-conjugated 27-nt double-stranded RNAs (dsRNAs) to facilitate cellular uptake and designed to stabilize mature miR-126 as previously reported. 18 The RNA oligonucleotides with a partial phosphorothioate backbone (*) and a cholesterol group (Chol) were synthesized as follows: miR-126 dsRNA sense:
The following control dsRNA included a random sequence of nucleotides and was not complementary to previously known miRNA: control dsRNA sense:
The dsRNAs were purchased from Hokkaido System Science (Sapporo, Japan). Anionic PLGA NPs encapsulated with miR-126 or miRcontrol were prepared by a previously reported emulsion solvent diffusion method in purified water. 15, 16, 19 The diameter and surface charge of the miR-126-loaded PLGA NPs were 322 nm and þ50 mV, respectively. The diameter and surface charge of the miR-control-loaded PLGA NPs were 329 nm and þ57 mV, respectively. The miR-126-loaded PLGA NPs contained 4.59% (wt/vol) miR-126, and the miR-control-loaded PLGA NPs contained 4.86% (wt/vol) miR-control.
Animal preparation and experimental protocol. The mice were randomly divided into five groups: a sham group, two control groups (scrambled miR-loaded PLGA NPs; 5 mg/50 mg), and two miR-126 groups (miR-126-loaded PLGA NPs; 5 mg/50 mg; Fig 1) . We assigned 24 mice per group, and 12 of 24 were used for laser Doppler perfusion imaging, 6 mice for day-3 analyses of real-time polymerase chain reaction (PCR), and 6 mice for day-7 analyses of real-time PCR or Western blotting. The animals were anesthetized with pentobarbital, 65 mg/kg intraperitoneally, for the surgical procedure as well as for laser Doppler measurements. A skin incision was made in the left hindlimb. The proximal femoral artery and the proximal portion of the saphenous artery were ligated. After all side branches were dissected free, the entire femoral artery was excised in all groups including the sham group. 20 We injected miR-126-loaded PLGA NPs or miR-control-loaded PLGA NPs into the ischemic thigh muscles just after induction of ischemia. We prepared 25 mL of solution including control-miR or miR-126 PLGA NPs for each animal. We divided the volume into 5 Â 5 mL and injected it into five different sites of the musculature. We did not optically observe acute local inflammatory responses after miR administration, which potentially relates to the initial burst of local delivery. 21 Hindlimb blood perfusion. Hindlimb blood perfusion was scanned using a laser Doppler perfusion image analyzer (OZ-1; OMEGAZONE, OMEGAWAVE Inc, Tokyo, Japan). Ischemic and nonischemic limb perfusion was measured 0 (post), 7, and 14 days after surgery. The ratio of ischemic to nonischemic hindlimb perfusion was calculated. Before analysis, we fully warmed the animals using a bed heater (5 minutes) to obtain consistent results free from temperature artifacts. 22 Immunohistochemical analysis. The mice were euthanized and perfusion fixed with 4% paraformaldehyde 14 days after surgery. The histologic evaluation was performed in 5-mm paraffin-embedded sections of the gastrocnemius muscle 14 days after hindlimb ischemia. Capillary density and arteriolar density in the ischemic muscle were determined by immunohistochemical staining with anti-mouse platelet endothelial cell adhesion molecule 1 antibody (CD31; Abcam, Cambridge, UK) and a-smooth muscle actin (a-SMA; Dako, Glostrup, Denmark), respectively. Digital images of five microscopic fields from four different sections from each animal were stored. Capillary density was expressed as the number of CD31-positive cells per square millimeter, and arteriolar density was expressed as the number of circumvented brown signals of a-SMA per square millimeter as previously described. 22 Quantitative real-time PCR analysis. The gastrocnemius muscle was explanted and preserved immediately in liquid nitrogen at 3 or 7 days after surgery. Total RNA was then extracted from the gastrocnemius muscle using TRIzol (Invitrogen, Carlsbad, Calif). miRNA was measured using TaqMan MicroRNA Assays (Applied Biosystems, Oakville, Ontario, Canada). Real-time PCR was performed on the StepOnePlus Real-Time PCR System (Applied Biosystems). miRNA expression levels were normalized by U6 small nuclear RNA expression. For the quantification of messenger RNA (mRNA), complementary DNA was synthesized using Verso cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, Mass), and analysis of mRNA expression levels was performed by a StepOnePlus Real-Time PCR System (Applied Biosystems) and THUNDERBIRD SYBR qPCR Mix (TOYOBO, Osaka, Japan). Expression was normalized by the housekeeping gene b-actin (the expression was stable).
ARTICLE HIGHLIGHTS
The primer sequences are listed in the Table. Customdesigned primers were purchased from Hokkaido System Science. The control 50-mg group was set as 1 in all cases. The analyses for miR-126 were performed on days 3 and 7, and those for SPRED1 and phosphoinositide 3-kinase regulatory subunit 2 (PI3KR2) were performed on day 7.
Western blotting. Muscle tissues were lysed using lysis buffer (100 mM Tris-HCl [pH 7.4], 75 mM NaCl, and 1% Triton X-100 [Nacalai Tesque, Kyoto, Japan]) with Complete Mini protease inhibitor (Roche, Basel, Switzerland), aprotinin (Sigma-Aldrich, St. Louis, Mo), 50 mM NaF, and 1 mM Na 3 VO 4 as previously reported. 18 Protein concentrations were quantified using a bicinchoninic acid protein assay kit (Bio-Rad, Hercules, Calif). Statistical analysis. The data were analyzed using JMP Pro 11 (SAS Institute, Cary, NC). All data are presented as mean 6 standard deviation. The laser Doppler data were tested with one-way analysis of variance. Differences between groups were determined with the Student t-test. Data were considered significant when P < .05.
RESULTS
Increased blood perfusion by the miR-126-loaded PLGA NP treatment. No deaths or leg necrosis was observed during the observation period. Laser Doppler perfusion imaging revealed that limb blood flow in the high-dose miR-126 group was higher than that in the other groups at 14 days after treatment (Fig 2, A) . The laser Doppler perfusion imaging index in the high-dose miR-126 group was significantly higher than in the other groups, including the low-dose miR-126 group, at 14 days after treatment (sham vs low-dose control vs high-dose control vs low-dose miR-126 vs high-dose miR-126: 0.62 6 0.09 vs 0.63 6 0.03 vs 0.58 6 0.05 vs 0.65 6 0.07 vs 0.72 6 0.07; P < .001; n ¼ 12; Fig 2, B) . No significant difference in laser Doppler perfusion imaging index was observed among the sham, low-dose control, high-dose control, and low-dose miR-126 groups.
Increased capillary and arteriolar density after miR-126-loaded PLGA NP treatment. CD31-positive lumen density, which indicates capillary angiogenesis, in the high-dose miR-126 group was significantly higher than in the other groups (sham vs control vs miR-126: 241 6 108 vs 211 6 45 vs 437 6 89; P < .01; n ¼ 6; Fig 3, A and B). Moreover, a-SMA-positive vessel density, which indicates arteriogenesis, in the high-dose miR-126 group was significantly higher than in the other groups (sham vs control vs miR-126: 13.2 6 4.7 vs 13.2 6 4.3 vs 35.2 6 12.7; P < .001; n ¼ 6; Fig 3, C and D) . The densities of capillary and arteriole in the high-dose miR-126 group were almost comparable with those in normal nonischemic mice hindlimb (Fig 3, A and C) .
miR-126 loaded PLGA NP treatment partially controlled VEGF receptor pathway activity. The miR-126 expression levels in the ischemic limb at 3 and 7 days after treatment were significantly higher in mice treated with miR-126-loaded PLGA NPs compared with those with scrambled miR, indicating the fair efficiency of local miR transduction and upregulation (control vs miR-126: day 3, 1.00 6 0.15 vs 2.27 6 0.53 [P < .05; n ¼ 6]; day 7, 1.00 6 0.11 vs 1.32 6 0.29 [P < .05; n ¼ 6] ; Fig 4, A) .
Next, we investigated the gene expression level of downstream molecules of the VEGF receptor pathway. SPRED1 mRNA expression levels on day 7 were significantly lower in miR-126-treated mice, which is consistent with previous reports that miR-126 downregulates SPRED1 (control vs miR-126: 1.00 6 0.05 vs 0.81 6 0.07; P < .05, n ¼ 6; Fig 4, B) . The protein level examined by Western blotting on day 7 also revealed the downregulation of SPRED1 (control vs miR-126: 0.36 6 0.09 vs 0.13 6 0.02; P < .05; n ¼ 6; Fig 4, D) . We also found that protein levels of pERK/ERK, which is negatively regulated by SPRED1, on day 7 were significantly higher in miR-126-treated mice (control vs miR-126: 0.29 6 0.10 vs 0.54 6 0.21; P < .05; n ¼ 6; Fig 4, E) . On the other hand, mRNA expression levels of PI3KR2, which is reported to be downregulated by miR-126, 9, 23, 24 were not affected by the miR-126 treatment at 7 days after treatment (control vs miR-126: 1.00 6 0.05 vs 0.84 6 0.13; P ¼ .2943; n ¼ 6; Fig 4, C) . Protein levels of pAKT/AKT negatively regulated by SPRED1 were also not affected at 7 days after treatment (control vs miR-126: 0.80 6 0.13 vs 0.95 6 0.14; P ¼ .4709; n ¼ 6; Fig 4, F) .
DISCUSSION
In this study, we showed that the sustained release of miR-126 with PLGA NPs significantly improved the hindlimb ischemia of mice. The improved recovery of blood flow was likely mediated by regulation of the VEGF receptor pathway by the in vivo overexpression of miR-126.
Recent studies have indicated that miRNAs play important regulatory roles in almost every physiologic process. The expression profiles of miRNAs in various cardiovascular diseases have been examined, 25 and several miRNAs have been reported to regulate vascular development and angiogenesis in endothelial cells. 26, 27 These findings encourage researchers to explore miRNA-based angiogenic therapies, which can control intracellular signaling pathways targeting the regulations of multiple mRNAs controlled by the miRNAs. The relationship between miR-126 and various cardiovascular diseases has been recently reported. 10, 24, 28 miR-126 is one of the miRNAs that are highly enriched in endothelial cells and is recognized to be important for regulating vascular integrity and angiogenesis by targeting SPRED1 and PI3KR2 in the VEGF receptor signaling pathway.
9,10 miR-126 would be an attractive therapeutic target for ischemic diseases. The DDS of miRNA is crucial for miRNA-based therapy. Although several techniques of targeted miRNA delivery exist, 19, 29, 30 the efficacy of the delivery techniques is still unclear, and the optimal delivery technique remains to be determined. The efficiency of miRNA-based therapy for proangiogenesis depends on sufficient and specific delivery to a target organ, such as the vascular endothelium. Furthermore, a viral vector-free method of miRNA delivery would be advantageous for the miRNA-based therapy. A PLGA delivery system is reported to be a viral vector-free method of gene delivery, 15, 16, 18 and the nucleic acids loaded in PLGA can gradually be released during the degradation after local administration. miR-126-loaded PLGA NP-mediated delivery increased neovascularization and improved tissue perfusion in a murine hindlimb ischemia model. Analysis of the neovascularization revealed increased capillary and arteriolar formation and improved limb perfusion. Investigations for the mechanisms underlying these effects revealed that miR-126 administration downregulated a reported direct target, SPRED1. It is reported that the downregulation of SPRED1 led to the activation of the MAPK/ERK pathway, 10 which contributed to the activation of angiogenesis-related genes. 31 Although it is not clearly shown in this study, it might be possible that the downregulation of SPRED1 after miR-126 administration into the murine hindlimb ischemia activated the MAPK/ERK-mediated angiogenesis. In contrast, another reported direct target of miR-126, PI3KR2, and the downstream pathway, including the activation of AKT, were not affected in the present experiments. The divergence in working pathways might be caused by unknown pathways mediated by miR-126 and should be further investigated.
There are several limitations in this study. First, we did not include the treatment group of miR-126 in saline (without PLGA). To clarify the precise effect of DDS mediated by PLGA, we should compare the therapeutic effect of miR-126 with or without PLGA and check the expression level of miR-126 in a later stage (after day 7), which will be performed in future studies. Second, the experiments represent an experimental acute-phase hindlimb ischemia without atherosclerosis, which is a common cause of clinical limb ischemia. We may need to further validate the therapeutic effect of miR-126 on disease model animals and clinical studies and include other functional evaluations, such as muscle volumetry or walking distance, in the future. Third, we employed a single administration of miR-126 PLGA NPs with only two doses (5 mg/50 mg). Optimal treatment dose and timing should be further investigated before clinical studies. Fourth, as arteriogenesis is clinically reported to be more relevant in blood flow recovery in limb ischemia, 32 it would be better to employ a more sensitive method for the quantification of arterioles, such as micro-computed tomography or angiography, than a-SMA staining. Last, there is the possibility that intramuscular administration may affect tissues other than the target of the present study. Moreover, the effect of miR-126 toward the unexpectedly transduced cells remains unknown. Although the possibility would be lower than with systemic administration, the unexpected effect of miR-126 and the distribution of miR-126 after administration should be clarified in future experiments.
CONCLUSIONS
The sustained release of miR-126 using PLGA NPs showed an excellent therapeutic potential in hindlimb ischemia in mice. This finding serves as a fundamental step for the development of future miRNA-based therapeutic angiogenesis for clinical limb ischemia.
We would like to thank Mr Shuichi Miyake (Kyoto University) for his technical support. Regulation of vascular endothelial cell growth factor (VEGF) receptor pathways after administration of microRNA-126 (miR-126)-loaded poly lactic-co-glycolic acid nanoparticles (PLGA NPs). A-C, Quantitative realtime polymerase chain reaction (PCR). A, miR-126 expression levels. n ¼ 6 in each group; day 3 (left panel) and day 7 (right panel). B, Sprouty-related EVH1 domain-containing protein 1 (SPRED1) messenger RNA (mRNA) expression levels on day 7. n ¼ 6 in each group. C, Phosphoinositide 3-kinase regulatory subunit 2 (PI3KR2) mRNA expression levels on day 7. n ¼ 6 in each group. D-F, Western blotting. D, Protein levels of SPRED1 on day 7. n ¼ 6 in each group. E, Protein levels of phosphorylated ERK on day 7. n ¼ 6 in each group. F, Protein levels of phosphorylated AKT on day 7. n ¼ 6 in each group. 
AUTHOR CONTRIBUTIONS

